Philadelphia-based Fox Chase Cancer Center has been named a Comprehensive Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine & Molecular Imaging. Fox Chase is the first center in Philadelphia and one of three in Pennsylvania to receive the designation.
Radiopharmaceutical therapy uses radioactive tracers to target and destroy cancer cells, reducing common side effects experienced while undergoing other cancer treatments, according to an Oct. 15 news release from Fox Chase.
The society's Comprehensive Radiopharmaceutical Therapy Center of Excellence designation signifies a center is an "in-depth, prestigious and well-equipped" facility for radiopharmaceutical therapy, the release said. The center must adhere to specific guidelines to maintain its designation.